Decoding biomedtech investment strategies

Speakers

Moderator's Profile:

Alice Chen, PhD, serves as Partner and Head of APAC at Accelerator Life Science Partners. Dr. Chen joined the firm in 2013 as a Principal, where she led portfolio company operations and provided executive oversight of preclinical development activities across the portfolio. Alice is actively involved in identifying and evaluating emerging biotechnology investment opportunities, and has played an instrumental role in the formation, oversight, and transaction of several Accelerator portfolio companies, including Acylin Therapeutics (asset acquisition by a global pharmaceutical company), Petra Pharma (acquired by a global pharmaceutical company), Nemean Pharma, Rodeo Therapeutics (acquired by Amgen Inc.), Magnolia Neurosciences, and Automera. Dr. Chen has served in various operational leadership roles across portfolio companies and is currently on the Board of Directors for Automera.

Speaker's Profile:

Dr. Yin is the Founding Partner of Trinity Innovation Bioventure Singapore (TIBS) and Trinity Innovation Fund (TIF). He is also the Chairman of TIBS. TIBS is a biotech venture capital firm focused on venture creation and early stage biotech investment, such asTransThera (02617.HK) , Ribo Lifescience (06938.HK) and ArgoBio etc. Axcynsis, NeuroVanda and Brano are biotechs built by TIBS with full operation in Singapore. Dr. Yin is an experienced biotech investor who was responsible for equity investments in the pharmaceutical and healthcare sector, such as CanSino, Ascentage, Bright-gene, Dizal, Ribo, and EpimAb. Prior to SDIC, Dr. Yin worked in both biotechnology and global multinational pharmaceutical companies, such as Novartis, where he led and managed innovative drug discovery projects. Jack holds a Ph.D. in Organic Chemistry from the National University of Singapore, and graduated with both M.Sc. and B.Sc. in Chemistry from Nankai University.

Speaker's Profile:

Nav joined Novo Holdings Asia in August 2021. He focusses on deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia. Prior to joining Novo Holdings Asia, Nav was a Director in Quadria Capital, a mid-market private equity firm focusing on healthcare investments in India and South East Asia. Before joining Quadria Capital, Nav was the Managing Director at Fosun, where he worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Nav started his investment career with Merrill Lynch in Hong Kong and moved to UBS Global Asset Management in Singapore before joining Fosun. Nav holds an MBA from Indian Institute of Management (IIM), Ahmedabad, in India and Bachelor of Technology from Indian institute of Technology (IIT), Kharagpur in India.

Speaker's Profile:

Colin is the Investment Director of Coronet Ventures. As part of Cedars Sinal Hospital's venture initiatives, he manages venture investments and venture building activities in Asia across biotech and medtech with a strategic direction for the US market. Colin's background is in healthcare startups in the US and Singapore, focusing on fund raising, medical device project management, operations, product design and development. His experience includes taking projects through conceptualization, verification, clinical trials, regulatory approvals, manufacturing and commercialization. Colin has managed and worked on a diverse range of projects from tissue engineering of vascular substitutes to ocular implants, glucose monitoring, endoscopy, orthopedic, and cardiovascular products. He has a Master's in Bioengineering from Stanford University and a Bachelor's in Biomedical Engineering from Northwestern University.